复星医药子公司复宏汉霖与上药控股达成战略合作，深化全域资源整合与业务联动
近日，复星医药子公司复宏汉霖与上药控股正式签署战略合作协议。双方将依托各自在生物医药创新与全产业链供应链服务领域的核心优势，深化全域资源整合与业务联动，通过高效产业协同提升优质药品可及性，深耕医疗服务价值，共筑健康未来。上海医药执行董事兼执行总裁李永忠先生、上药控股副总经理宋潞潞女士，复宏汉霖执行董事、首席执行官朱俊博士，董事会秘书、公众传播总经理王燕女士，商务部副总经理刘素坚女士等出席了签约仪式。
复宏汉霖执行董事、首席执行官
朱俊博士表示
上药控股是复宏汉霖重要的战略伙伴。本次合作将整合双方优势资源，实现从研发创新到商业服务的高效衔接，真正打通创新药从实验室到临床应用的‘最后一公里’。未来，复宏汉霖将继续坚持以创新药为核心驱动，通过与合作伙伴的深度战略协同，为提升药品可及性、惠及患者贡献更大力量。
上海医药执行董事兼执行总裁
李永忠先生表示
复宏汉霖坚持创新引领，产品研发与产业布局成果斐然。上药控股深耕医药流通领域，以专业能力与稳健经营保持行业领先。本次战略合作将推动双方实现更高水平的协同发展，期待依托双方多元资源，推动复宏汉霖的研发创新与上药控股的商业平台深度融合，让更多优质生物药惠及广大患者。
根据协议，双方将以创新成果产业转化为核心、以全链条商业运营为支撑，聚焦市场准入、终端服务和创新支付等维度开展深度协同——通过深化渠道布局、共享市场营销资源、探索多元化支付模式，持续推动优质医药成果惠及更多患者。同时，双方也将积极拓展药品上市前商业铺垫及海外市场拓展等前沿领域的合作，携手构建更加高效、可持续的医药健康生态。
未来，复宏汉霖将持续立足创新与产业实际，携手产业链上下游合作伙伴拓展合作广度、挖掘协同深度，持续优化产品布局与运营效能，构筑企业长远发展核心竞争力，推动生物医药产业提质升级。
关于复宏汉霖
复宏汉霖（2696.HK）是一家国际化创新生物制药企业，致力于为全球患者提供高品质、可负担的生物药，产品覆盖肿瘤、自身免疫疾病、眼科疾病等领域。自2010年成立以来，公司已构建涵盖全球研发、临床、注册、生产及商业化的全产业链平台，拥有全球员工近4,000人，并在中国、美国和日本等多地设有运营及分支机构。依托生物类似药形成的稳健现金流反哺创新研发，复宏汉霖正稳步迈入“全球化2.0”阶段，持续打造可复制、可持续的全球增长模式。截至2026年初，公司共有10款产品在全球60个国家和地区获批上市，其中7款已在中国获批。在欧美主流生物药市场，复宏汉霖亦取得多项里程碑式突破，已有4款产品获得美国FDA批准、4款产品获得欧盟EMA上市授权，充分体现了公司在研发体系、质量管理及生产能力方面已全面对标国际最高标准。
在创新驱动方面，复宏汉霖依托上海、美国等多地协同布局的研发体系，构建了多元化、平台化的创新技术矩阵，覆盖免疫检查点抑制剂、免疫细胞衔接器（包括多特异性TCE）、抗体偶联药物（ADC）以及AI驱动的早期研发平台等前沿方向。目前，公司拥有50余项处于早期阶段的创新资产，其中约70%具备同类最佳（Best-in-Class）潜力，并在全球同步推进30余项临床研究。核心产品H药 汉斯状®（斯鲁利单抗，欧洲商品名：Hetronifly®）作为全球首个获批一线治疗小细胞肺癌的抗PD-1单抗，正加速全球布局，已在全球40余个市场获批上市；同时，多款潜力创新资产，包括PD-L1 ADC HLX43及新表位HER2单抗HLX22正全面推进全球关键性临床研究。依托通过中、欧、美三地GMP认证的生产体系，复宏汉霖已建成总产能达84,000升的生物药生产平台，形成覆盖全球六大洲的稳定供应网络。未来，复宏汉霖将始终坚持以患者为中心，聚焦未满足的临床需求，持续推动创新成果向临床价值与患者可及转化，在全球生物医药创新生态中创造长期而稳健的价值。
关于上药控股
上药控股是一家以医药健康服务为核心的全国性现代医药供应链服务企业。公司已发展成为中国规模大、网络广、实力强的医药经营企业之一。上药控股以建立全国性的终端网络为基础，着力推进医院供应链服务，构建新的产业优势。公司深化服务创新，加快产业突破，致力于构建国家级的医药供应链服务平台。
Henlius and SPH Join Forces in Strategic Partnership for a Healthier Future
Recently, Henlius and Shanghai Pharmaceutical Co., Ltd. (SPH) officially signed a strategic cooperation agreement. Leveraging their respective core strengths in biomedical innovation and full-industry-chain supply chain services, the two parties will deepen resource integration and business collaboration across all dimensions. Through efficient industrial synergy, the partnership aims to enhance access to high-quality medicines, deliver greater service value, and work together toward a healthier future. The signing ceremony was attended by Mr. Yongzhong Li, Executive Director and President of Shanghai Pharmaceuticals; Ms. Lulu Song, Deputy General Manager of SPH; Dr. Jason Zhu, Executive Director and CEO of Henlius; Ms. Nancy Wang, Board Secretary and General Manager of Public Relations; and Ms. Susie Liu, Deputy General Manager of Distribution Management.
Dr. Jason Zhu, Executive Director and CEO of Henlius, stated: “SPH is a key strategic partner for Henlius. This collaboration will integrate the advantages of both sides to create an efficient bridge between R&D innovation and commercial services, closing the 'last mile' from drug development to clinical application. Moving forward, Henlius will continue to prioritize innovative drugs as our core driver and, through deep strategic synergy with partners contribute even greater efforts to improving drug accessibility and benefiting patients.”
Mr. Yongzhong Li, Executive Director and President of Shanghai Pharmaceuticals, commented: “Henlius has consistently pursued innovation-led growth, achieving remarkable results in product development and business expansion. SPH, with its deep roots in the pharmaceutical distribution sector, maintains industry leadership through professional expertise and stable operations. This strategic partnership will elevate our collaboration to a new level of coordinated development. We look forward to leveraging our combined resources to drive the deep integration of Henlius’ R&D innovation with SPH’s commercial platform, bringing more high-quality biologics to patients.”
According to the agreement, the two parties will focus on the industrial transformation of innovative achievements, supported by full-chain commercial operations. The collaboration will center on key areas such as market access, terminal services, and innovative payment models—by optimizing distribution networks, sharing marketing resources, and exploring diversified payment mechanisms to continuously deliver high-quality medical innovations to more patients. Additionally, both sides will actively expand cooperation into frontier areas such as pre-launch commercial planning and international expansion, jointly building a more efficient and sustainable healthcare ecosystem.
Looking ahead, Henlius will remain committed to innovation aligned with industry realities, working closely with partners across the value chain to broaden the scope and deepen the impact of collaborations. By continuously optimizing its product portfolio and operational efficiency, the company aims to build long-term core competitiveness and drive the upgrading and advancement of the biomedical industry.
About Henlius
Shanghai Henlius Biotech, Inc. (2696.HK) is a global, innovation-driven biopharmaceutical company committed to delivering high-quality, affordable biologic therapies to patients worldwide. The Company focuses on major disease areas including oncology, autoimmune diseases, and ophthalmic diseases. Founded in 2010, Henlius has established an integrated, end-to-end biopharmaceutical platform encompassing global R&D, clinical operations, regulatory affairs, manufacturing, and commercialisation. The Company employs nearly 4,000 people globally and operates across multiple regions, including China, the United States, and Japan. Leveraging the stable cash flow generated from its biosimilar portfolio to support innovation, Henlius is steadily advancing into its “Globalisation 2.0” phase, building a scalable and sustainable global growth model. As of early 2026, Henlius has achieved regulatory approvals for 10 products across 60 countries and regions worldwide, including seven approvals in China. The Company has also reached multiple milestones in major biopharmaceutical markets, with four products approved by the U.S. Food and Drug Administration (FDA) and four products authorized by the European Medicines Agency (EMA), reflecting its globally aligned R&D capabilities, quality systems, and manufacturing standards.
Driven by innovation, Henlius has built a diversified, platform-based technology ecosystem through coordinated R&D efforts across Shanghai, the United States, and other regions. Its innovation platforms span immune checkpoint inhibitors, immune cell engager technologies (including multispecific T cell engagers), antibody-drug conjugates (ADCs), and AI-enabled early discovery platforms. The Company currently has more than 50 early-stage innovative assets, approximately 70% of which are expected to be best-in-class, with over 30 clinical trials ongoing globally. Henlius’ core product, serplulimab (trade name: Hetronifly® in Europe), is the world’s first anti–PD-1 mAb approved for first-line treatment of small cell lung cancer and has been approved in more than 40 markets worldwide with an accelerated globalisation process. In parallel, multiple high-potential innovative assets—including the PD-L1 ADC HLX43 and the novel epitope anti-HER2 mAb HLX22—are advancing through global pivotal clinical development. Supported by a biologics manufacturing network with a total capacity of 84,000L and GMP certifications from regulatory authorities in China, Europe, and the United States, Henlius has established a stable global supply system serving six continents. Guided by a patient-centred mission, Henlius remains focused on addressing unmet medical needs and translating scientific innovation into meaningful clinical value and patient access, contributing sustainably to the global biopharmaceutical ecosystem.
To learn more about Henlius, visit https://www.henlius.com/en/ and connect with us on LinkedIn at https://www.linkedin.com/company/henlius/.
About SPH
Shanghai Pharmaceutical Co., Ltd. is a national modern pharmaceutical supply chain service enterprise focused on healthcare services. It has grown to become one of China’s largest, most extensively networked and most competitive pharmaceutical enterprises. Building on its national end-market network, the company is committed to advancing hospital supply chain services and forging new industrial advantages. By deepening service innovation and accelerating industrial breakthroughs, the company strives to build a national-level pharmaceutical supply chain service platform.
